The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?

Abstract

This pattern of staining raises concern for a possible contributing role of exogenous estrogen therapy in tumorigenesis. As awareness of gender dysphoria and acceptance of gender reassignment surgery has seen a recent increase, the unique needs of this population must be recognized. Prostate 77:824-828, 2017. © 2017 Wiley Periodicals, Inc.

Breast and reproductive cancers in the transgender population: a systematic review

“…Case reports . Eight case reports have been published, including a report covering Gooren and Morgentaler's case . The average diagnosis age was 64.8 years.…”

“…Eight case reports have been published, including a report covering Gooren and Morgentaler's case. [37][38][39][40][41][42][43][44] The average diagnosis age was 64.8 years. In all, 62.5% were prostatic adenocarcinomas and 37.5% were unspecified.…”

“…In all, 62.5% were prostatic adenocarcinomas and 37.5% were unspecified. Six transwomen had received hormones for 10-41 years, [39][40][41][42][43][44] and six had undergone gender confirmation surgery including orchiectomy, with the mean age for orchiectomy being 48 years. [37][38][39][40][41][42] Five studies described hormone use after diagnosis, with two transwomen discontinuing 29,44 and three continuing hormone use.…”

“…Six transwomen had received hormones for 10-41 years, [39][40][41][42][43][44] and six had undergone gender confirmation surgery including orchiectomy, with the mean age for orchiectomy being 48 years. [37][38][39][40][41][42] Five studies described hormone use after diagnosis, with two transwomen discontinuing 29,44 and three continuing hormone use. [40][41][42] Follow-up data were provided by five studies: three transwomen showed no evidence of recurrence, 39,41,44 recurrence occurred in one transwoman, 43 and one transwoman died of metastatic disease.…”

“…[37][38][39][40][41][42] Five studies described hormone use after diagnosis, with two transwomen discontinuing 29,44 and three continuing hormone use. [40][41][42] Follow-up data were provided by five studies: three transwomen showed no evidence of recurrence, 39,41,44 recurrence occurred in one transwoman, 43 and one transwoman died of metastatic disease. 42…”